Scott Hutton Sells 13,278 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSXGet Rating) CEO Scott Hutton sold 13,278 shares of Biodesix stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $1.83, for a total transaction of $24,298.74. Following the transaction, the chief executive officer now owns 43,866 shares in the company, valued at approximately $80,274.78. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NASDAQ:BDSX opened at $1.51 on Thursday. Biodesix, Inc. has a one year low of $1.31 and a one year high of $16.40. The business’s 50-day simple moving average is $1.86 and its 200 day simple moving average is $3.95. The stock has a market cap of $47.28 million, a price-to-earnings ratio of -0.96 and a beta of 1.50.

Biodesix (NASDAQ:BDSXGet Rating) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.12). During the same period last year, the business posted ($0.23) earnings per share. As a group, equities research analysts expect that Biodesix, Inc. will post -1.13 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BDSX. Morgan Stanley raised its stake in Biodesix by 148.9% during the third quarter. Morgan Stanley now owns 108,523 shares of the company’s stock valued at $892,000 after buying an additional 64,919 shares in the last quarter. Millennium Management LLC acquired a new stake in Biodesix during the fourth quarter valued at approximately $275,000. Two Sigma Investments LP acquired a new stake in Biodesix during the third quarter valued at approximately $321,000. Chicago Capital LLC acquired a new stake in Biodesix during the fourth quarter valued at approximately $143,000. Finally, Two Sigma Advisers LP acquired a new stake in Biodesix during the third quarter valued at approximately $156,000. Hedge funds and other institutional investors own 85.26% of the company’s stock.

BDSX has been the topic of several recent research reports. Cowen initiated coverage on shares of Biodesix in a report on Wednesday, April 20th. They set an “outperform” rating on the stock. Canaccord Genuity Group cut their price objective on shares of Biodesix from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, February 15th. BTIG Research reissued a “buy” rating and issued a $10.00 price objective (down from $17.00) on shares of Biodesix in a research report on Thursday, April 14th. Cowen began coverage on Biodesix in a research report on Wednesday, April 20th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research cut Biodesix from a “buy” rating to a “hold” rating in a research note on Thursday, March 17th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.95.

Biodesix Company Profile (Get Rating)

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Featured Articles

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.